180 Life Sciences Corp.
ATNF
$1.05
-$0.0301-2.79%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.85M | 6.70M | 8.24M | 10.69M | 14.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.37M | 8.93M | 10.77M | 13.48M | 17.66M |
| Operating Income | -6.37M | -8.93M | -10.77M | -13.48M | -17.66M |
| Income Before Tax | -3.13M | -14.90M | -18.59M | -22.28M | -43.74M |
| Income Tax Expenses | -4.40K | -2.35M | -2.35M | -2.35M | -3.29M |
| Earnings from Continuing Operations | -3.12 | -12.55 | -16.24 | -19.94 | -40.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.12M | -12.55M | -16.24M | -19.94M | -40.45M |
| EBIT | -6.37M | -8.93M | -10.77M | -13.48M | -17.66M |
| EBITDA | -6.29M | -8.83M | -10.66M | -13.37M | -17.54M |
| EPS Basic | -4.49 | -28.16 | -41.54 | -64.01 | -247.20 |
| Normalized Basic EPS | -3.14 | -7.89 | -16.14 | -30.18 | -53.59 |
| EPS Diluted | -4.49 | -28.17 | -41.55 | -64.02 | -247.21 |
| Normalized Diluted EPS | -3.14 | -7.89 | -16.14 | -30.18 | -53.59 |
| Average Basic Shares Outstanding | 3.16M | 2.60M | 1.96M | 1.51M | 1.01M |
| Average Diluted Shares Outstanding | 3.16M | 2.60M | 1.96M | 1.51M | 1.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
